生命科学仪器2024，Vol.22Issue(4)：140-141,144,3.DOI:10.11967/2024220848
司美格鲁肽与达格列净治疗2型糖尿病合并非酒精性脂肪性肝病患者的疗效对比
Comparison of the Therapeutic Effects of Smeagoutide And Dapagliflozin in the Treatment of Patients with Type 2 Diabetes Mellitus Complicated with Nonalcoholic Fatty Liver Disease
王源源1
作者信息
- 1. 南华大学附属第一医院内分泌科,湖南衡阳 421000
- 折叠
摘要
Abstract
Objective:To compare the clinical efficacy of smegliptide and Dapagliflozin in treating patients with type 2 diabe-tes mellitus(T2DM)complicated with nonalcoholic fatty liver disease(NAFLD).Methods:102 patients with T2DM com-plicated with NAFLD admitted to the First Affiliated Hospital of South China University from February 2022 to March 2023 were selected and divided into group A and group B according to the medication regimen,with 51 cases in each group.Group A was treated with Dapagliflozin,while Group B was treated with Smegliptide.The clinical therapeutic effects of the two groups were compared.Results:Compared with before treatment,the body weight、body mass index、waist circumference、fasting blood glucose、insulin resistance index、alanine aminotransferase、aspartate aminotransferase、plasma cholesterol、plasma triglyceride and visceral adipose tissue area of the two groups decreased after treatment,and the improvement degree of group A was obviously better than that of group B,P<0.05.The total effective rate in group A was higher than that in group B,P<0.05.Conclusion:Compared with Dapagliflozin,Smegliptide is more effective in treating T2DM patients complicated with NAFLD,which can effectively control the blood sugar level,lose weight and improve their liver function.关键词
2型糖尿病/非酒精性脂肪性肝病/司美格鲁肽/达格列净Key words
Type 2 diabetes mellitus/Nonalcoholic fatty liver disease/Smegliptide/Dapagliflozin分类
医药卫生引用本文复制引用
王源源..司美格鲁肽与达格列净治疗2型糖尿病合并非酒精性脂肪性肝病患者的疗效对比[J].生命科学仪器,2024,22(4):140-141,144,3.
